Clinical trials: Osteopenia, Osteoporosis
Osteoporosis, Postmenopausal, Osteoporosis
Preventing Osteoporosis Using Denosumab
The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
- Trial name
- PROUD (NCT02753283)
- Testing
- denosumab, Calcium and Vitamin D
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Susan L. Greenspan
Osteoporosis
Denosumab Adherence Preference Satisfaction Study
The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12…
- Trial name
- NCT00518531
- Testing
- alendronate, denosumab
- Volunteers
- 250 people
- Sponsor
- Amgen
Osteoporosis, Osteopenia
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects…
- Trial name
- NCT00330460
- Testing
- Alendronate, Denosumab
- Volunteers
- 1,189 people
- Sponsor
- Amgen
Refractory Multiple Myeloma
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
This phase II trial studies the side effects and how well tivantinib works in treating patients with relapsed, or relapsed and refractory multiple myeloma.
- Trial name
- NCT01447914
- Testing
- Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Osteopenia, Bone Disease, Metabolic
Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia
The purpose of this study is to investigate whether the use of alkali compounds, i.e. potassium citrate (K3C6H5O7, hereinafter KCitr) is effective in preventing the progression of osteopenia.
- Trial name
- ACAROS (NCT02731820)
- Testing
- Potassium citrate, Vitamin D3, Calcium carbonate
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Ortopedico Rizzoli
Osteoporosis
Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
- Trial name
- 2MD-3H-2B (NCT00715676)
- Testing
- DP001
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Deltanoid Pharmaceuticals
Hematological Malignancies
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
The goal of this clinical research study is to see if ibandronate can help to slow the rate of bone loss that may occur in patients who have received a bone marrow transplant for blood cancer.
- Trial name
- NCT00824993
- Testing
- Ibandronate, Vitamin Supplements
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Low Bone Mineral Density, Postmenopausal Osteoporosis
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low…
- Trial name
- NCT00896532
- Testing
- Alendronate, Teriparatide, Romosozumab
- Volunteers
- 419 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
Summary: The investigators propose a randomized controlled open label study of teriparatide in men or women with rheumatoid arthritis and joint erosions.
- Trial name
- TERA (NCT01400516)
- Testing
- Teriparatide, calcium citrate, Vitamin D
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brigham and Women's Hospital
Osteoporosis, Osteopenia
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized…
- Trial name
- TERIZOL (NCT01153425)
- Testing
- Virtual Bone Biopsy, Teriparatide, Zoledronic Acid
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pennsylvania
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion…
- Trial name
- NCT01267279
- Testing
- Zoledronic acid
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Spokane Joint Replacement Center
Low Bone Density
Stem Cell Recruitment in Osteoporosis Therapy
Osteoporosis is an important health problem in the rapidly-aging demographic. Fragility fractures are devastating consequences of osteoporosis.
- Trial name
- NCT01656629
- Testing
- Teriparatide, Alendronate, calcium and vitamin D
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Johns Hopkins University
Postmenopausal Osteoporosis
Study of Transitioning From Alendronate to Denosumab
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab.
- Trial name
- NCT00377819
- Testing
- alendronate, Denosumab (AMG 162)
- Volunteers
- 504 people
- Sponsor
- Amgen
Renal Insufficiency
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.
- Trial name
- NCT00580047
- Testing
- Zoledronic Acid, Calcium with vitamin D, Alendronate
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Nebraska
Postmenopausal, Osteopenia
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
The primary objective of this study was to assess the safety, tolerability, and immunogenicity potential of romosozumab following multiple subcutaneous (SC) administrations in healthy men and postmenopausal women with low bone…
- Trial name
- NCT01825785
- Testing
- Romosozumab
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Osteopenia
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
- Trial name
- NCT00132808
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
Exercise-related Amenorrhea
Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
One aim of this study is to determine changes in body composition and hormones that differentiate athletes who stop getting their periods versus those who continue to get their periods and non-athletes.
- Trial name
- NCT00946192
- Testing
- Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis
A Study of LY2541546 in Women With Low Bone Mineral Density
The primary objectives of this study include evaluating the dose response of LY2541546 using bone mineral density (BMD) change from baseline as compared to placebo and evaluating the overall safety and tolerability of LY2541546…
- Trial name
- NCT01144377
- Testing
- LY2541546
- Where
- 8 sites in United States, Denmark and 3 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company